Replies to post #94633 on MyDx Inc. (fka MYDX)

[atpsylee]

Be careful w the A word. It might ruffle some feathers. An acquisition seems most likely here.

[Bed Bath & Beyonce]

In case this is a serious question.....

Because the Securities and Exchange Act and Rule 144 require companies be current on their reports for at least 90 days in order to do such sales or transactions.

Further, companies don’t just call and offer money to buy another without digging deep. They sign NDAs and look at each others books... very closely. And the books would probably show some really dirty laundry not in the Ks or Qs (such as the default judgments and cases in active litigation).

And they sure as hell are going to want to know why the company sued Dewald and Sanzeri for $29M and came out with only a $5K settlement. Additionally, how much was spent to litigate that case and whether the company was required to reimburse Jerome Dewald for his legal expenses, and for how much. And how and why the company was forced to settle the $29M case for $5K to a defendant that, according to the court website, never had legal representation.

Further, companies are going to want to know where every single penny is spent, why and how. Same goes for every single share of the 4.64B+ OS right now.

Companies are going to ask why AeroDX, AquaDX OrganaDX have been talked about in interviews done by Yazbeck, in pump pieces, prospectus documents and in the financials dating back to 2015. Companies are going to want to know where things are with those and why after four years, they’re still “coming soon.”

Companies are going to want to know why MYDX spent at least $1M to market a product in China in 2017 that here in late 2019 still hasn’t been delivered to American customers.

Companies are going to want to know the details and see the paperwork for the Bright Light Marketing deals, the depth of the relationship with Harry Tajyar (someone who has been on the SEC’s radar for awhile now, and I believe has active complaint against him), and other people involved in 2016 and 2017 business dealings.

Companies are going to ask about the Phoenix debt and court cases in 2016 in Florida, they’re going to ask about the Section 3(a)(10) exemptions MYDX appears to believe they and exempt from in 2016 and 2017 and the details behind those people paid for “crisis communications.”

Companies are going to want to know why the vape pen has been “coming soon” since April 2017 and its progress. They’re going to ask much harder, pointed and detailed questions than read here.

Companies are going to want to know why MYDX said it would conduct Israeli Clinical Trials, produce results in Q3 2018, and why there are no results one year later.

Companies are going to want to know why the former MYDX Chief Medical Officer resigned after seven months. They’re going to want to know why she filed a counter-claim against the company. That’s active litigation, companies are not going to overlook that, they’re going to want to know if there’s truth and Yazbeck’s side of the story his side of the story when it comes to the serious accusations of him misrepresenting himself and spending funds outside of intended purposes of Jessica Peatross’ personal business.

Companies are going to want to know why MYDX paid so much to the Mr. Cannabis Group and for the first full quarter of their tenure only brought in $1,539 of Q1 2019 revenue. They’re going to want to know why there were total operating expenses of $495K to show for $1,539 in revenue.

They’re also going to want to know why over $145K in cash and shares was given to Erai Beckmann to consult, advise and promote a product (the pen) in 2018 that is still not available.

AND, they’re going to want to know why the Q1 2019 10-Q was filed late and why the company has yet to file its Q2 2019 financials.

Lastly, a company is going to want to know from Yazbeck what the value is in a company that has $12M in debt, a deficit of $40M and is on track for $6,156 of annual revenue.

So if Yazbeck can produce all that information, then why doesn’t he simply file the 10-Q? He has the information and denies Shareholders their right to know.

To emphasize the opening point, the company is delinquent in its financials, the most basic of requirements in order to be acquired.

That’s why.

[VerifyandTrust]

No acquisition can occur while 10-Qs are delinquent.

Nor would any company or person be dumb enough to acquire SCAMydx.

Can't say the same for about 10-15 "investors"...aka victims.

[Frayed Knot]

I certainly hope that is not a serious question.

[Bed Bath & Beyonce]

In case this is a serious question.....

Because the Securities and Exchange Act and Rule 144 require companies be current on their reports for at least 90 days in order to do such sales or transactions.

Further, companies don’t just call and offer money to buy another without digging deep. They sign NDAs and look at each others books... very closely. And the books would probably show some really dirty laundry not in the Ks or Qs (such as the default judgments and cases in active litigation).

And they sure as hell are going to want to know why the company sued Dewald and Sanzeri for $29M and came out with only a $5K settlement. Additionally, how much was spent to litigate that case and whether the company was required to reimburse Jerome Dewald for his legal expenses, and for how much. And how and why the company was forced to settle the $29M case for $5K to a defendant that, according to the court website, never had legal representation.

Further, companies are going to want to know where every single penny is spent, why and how. Same goes for every single share of the 4.64B+ OS right now.

Companies are going to ask why AeroDX, AquaDX OrganaDX have been talked about in interviews done by Yazbeck, in pump pieces, prospectus documents and in the financials dating back to 2015. Companies are going to want to know where things are with those and why after four years, they’re still “coming soon.”

Companies are going to want to know why MYDX spent at least $1M to market a product in China in 2017 that here in late 2019 still hasn’t been delivered to American customers.

Companies are going to want to know the details and see the paperwork for the Bright Light Marketing deals, the depth of the relationship with Harry Tajyar (someone who has been on the SEC’s radar for awhile now, and I believe has active complaint against him), and other people involved in 2016 and 2017 business dealings.

Companies are going to ask about the Phoenix debt and court cases in 2016 in Florida, they’re going to ask about the Section 3(a)(10) exemptions MYDX appears to believe they and exempt from in 2016 and 2017 and the details behind those people paid for “crisis communications.”

Companies are going to want to know why the vape pen has been “coming soon” since April 2017 and its progress. They’re going to ask much harder, pointed and detailed questions than read here.

Companies are going to want to know why MYDX said it would conduct Israeli Clinical Trials, produce results in Q3 2018, and why there are no results one year later.

Companies are going to want to know why the former MYDX Chief Medical Officer resigned after seven months. They’re going to want to know why she filed a counter-claim against the company. That’s active litigation, companies are not going to overlook that, they’re going to want to know if there’s truth and Yazbeck’s side of the story his side of the story when it comes to the serious accusations of him misrepresenting himself and spending funds outside of intended purposes of Jessica Peatross’ personal business.

Companies are going to want to know why MYDX paid so much to the Mr. Cannabis Group and for the first full quarter of their tenure only brought in $1,539 of Q1 2019 revenue. They’re going to want to know why there were total operating expenses of $495K to show for $1,539 in revenue.

They’re also going to want to know why over $145K in cash and shares was given to Erai Beckmann to consult, advise and promote a product (the pen) in 2018 that is still not available.

AND, they’re going to want to know why the Q1 2019 10-Q was filed late and why the company has yet to file its Q2 2019 financials.

Lastly, a company is going to want to know from Yazbeck what the value is in a company that has $12M in debt, a deficit of $40M and is on track for $6,156 of annual revenue.

So if Yazbeck can produce all that information, then why doesn’t he simply file the 10-Q? He has the information and denies Shareholders their right to know.

To emphasize the opening point, the company is delinquent in its financials, the most basic of requirements in order to be acquired.

That’s why.